Featured Image

Life science incentives; UAE vs Central Europe

UAE has become one of the leading Middle Eastern countries in the biotechnology and pharmaceutical industry due to its heavy investment and development in the sector. In particular, the Dubai Free Zones and the …
Featured Image

CDx expert: “Genomics might only be the tip of the iceberg.”

It will soon be 25 years since the first CDx assay came to the market paving the way for the start of the era of personalized treatment. We have discussed the last 25 years …
Featured Image

The 4 most expensive single-dose drugs in 2022

In 2019, Novartis’s gene therapy Zolgensma has made news as the „most expensive single-dose drug ever“ with $2.125 million. Just 3 years later, as of November 2022, bluebird bio’s Skysona with the price tag …
Featured Image

NGS in clinical routine – where are we in 2022?

Next-generation sequencing (NGS)—a form of DNA sequencing that can examine millions of DNA molecules simultaneously—is proving to be crucial to the successful execution of the concept of precision medicine in oncology but its utility …
Featured Image

Life science dealmaking in 2022

The first year with eased-up COVID-19 restrictions, but with significant economic crisis. How did the life science dealmaking fare in the first half of 2022, following the banner year of 2021?  Decrease in IPOs, …
Featured Image

A year with MDR, does it stifle innovation?

The MD Regulation (MDR) 2017/745 is a recent EU directive on medical devices which entered into full force on 26th May 2021 after a transition period of three years, extended in early 2020 for …
Featured Image

Companion diagnostics – status in 2022 and future outlook

Companion diagnostics (CDx) is used as a companion to a therapeutic agent to determine its applicability (e.g. predict response to therapy, toxicity...) to a specific person. Commonly, companion diagnostics is named as one of …
Featured Image

7.9% of drugs entering clinical development were approved by FDA over the past decade.

Clinical research success rates of different disease areas have far-reaching implications in the structure of corporate R&D budgets, pharmaceutical asset valuation and, eventually, M&A activity. The report published in February 2021 considers success rates of clinical …
Featured Image

Top 3 news from ASCO 2022

The 2022 annual conference of the American Society of Clinical Oncology (ASCO) was held in Chicago between June 3rd-7th, widely recognised as one of the most important oncology gatherings worldwide and perhaps the most …
Featured Image

IVDR is here – 5 major changes to look out for

The In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746 is the new EU legislation applicable to in vitro diagnostic (IVD) medical devices (shortened to IVDs here for simplicity). IVDR officially entered into force on 25th May 2017 …
Featured Image

Diagnostics with strong presence in the top 10 healthcare trends by CADTH

Canadian Health Technology Assessment (HTA) agency CADTH has recently published a "Horizon Scan" naming health technology trends with expected large impact on Canada that have the potential to harness large volumes of data, improve …
Featured Image

What impact did COVID-19 really have on the diagnostics market?

The black swan event nobody could have really predicted. 400 million cases around the world and great strain on healthcare systems, physical and mental capacities of people globally. Could there be a silver lining to the …


ambiom s.r.o.
Karpatské námestie 7770/10A
831 06 Bratislava
IČO: 54219035


+421 948 652 276



Back to top Arrow